[go: up one dir, main page]

ATE372128T1 - Angiogene proteine aus onchocerca volvulus sowie deren verwendung - Google Patents

Angiogene proteine aus onchocerca volvulus sowie deren verwendung

Info

Publication number
ATE372128T1
ATE372128T1 AT01920807T AT01920807T ATE372128T1 AT E372128 T1 ATE372128 T1 AT E372128T1 AT 01920807 T AT01920807 T AT 01920807T AT 01920807 T AT01920807 T AT 01920807T AT E372128 T1 ATE372128 T1 AT E372128T1
Authority
AT
Austria
Prior art keywords
asp
tissue
factor
present
angiogenic proteins
Prior art date
Application number
AT01920807T
Other languages
English (en)
Inventor
Sara Lustigman
Eric Pearlman
Thomas Unnasch
Original Assignee
New York Blood Ct Inc
Univ Case Western Reserve
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc, Univ Case Western Reserve, Uab Research Foundation filed Critical New York Blood Ct Inc
Application granted granted Critical
Publication of ATE372128T1 publication Critical patent/ATE372128T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01920807T 2000-04-03 2001-03-27 Angiogene proteine aus onchocerca volvulus sowie deren verwendung ATE372128T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/541,759 US6723322B1 (en) 2000-04-03 2000-04-03 Angiogenic Onchocerca volvulus proteins and uses thereof

Publications (1)

Publication Number Publication Date
ATE372128T1 true ATE372128T1 (de) 2007-09-15

Family

ID=24160920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920807T ATE372128T1 (de) 2000-04-03 2001-03-27 Angiogene proteine aus onchocerca volvulus sowie deren verwendung

Country Status (7)

Country Link
US (1) US6723322B1 (de)
EP (1) EP1267917B1 (de)
AT (1) ATE372128T1 (de)
AU (2) AU4782501A (de)
CA (1) CA2403985C (de)
DE (1) DE60130326T2 (de)
WO (1) WO2001074385A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005122739A2 (en) * 2004-06-15 2005-12-29 The New York Blood Center, Inc. Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
WO2007111333A1 (ja) * 2006-03-29 2007-10-04 Toyo Boseki Kabushiki Kaisha 核酸導入時の細胞障害を低減する方法
US20190069528A1 (en) * 2016-03-21 2019-03-07 The George Washington University Engineered human hookworms as a novel biodelivery system for vaccines and biologicals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis

Also Published As

Publication number Publication date
CA2403985C (en) 2012-05-29
DE60130326T2 (de) 2008-05-29
EP1267917A4 (de) 2004-06-09
CA2403985A1 (en) 2001-10-11
AU4782501A (en) 2001-10-15
EP1267917A1 (de) 2003-01-02
DE60130326D1 (de) 2007-10-18
AU2001247825B2 (en) 2005-01-06
EP1267917B1 (de) 2007-09-05
US6723322B1 (en) 2004-04-20
WO2001074385A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
ATE277034T1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
CY1107453T1 (el) Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις
EP1411118A4 (de) Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
ATE478670T1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
DE60127656D1 (de) Integrin antagonisten
DE69839060D1 (de) Vegi, ein inhibitor der angiogenese und des tumorwachstums
ATE336485T1 (de) Substituierte heterocyclen und deren verwendung in arzneimitteln
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
AR021946A1 (es) Composiciones que contienen feniramina y metodo para el tratamiento de las respuestas alergicas
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE499098T1 (de) Verwendung von parp-1-hemmern
ATE395433T1 (de) Screeningverfahren für geeignete wirkstoffe
DE60236212D1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
ATE460166T1 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
EP1742643A4 (de) Modulation der glukose-6-phosphatase-translokase-expression
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
ATE372128T1 (de) Angiogene proteine aus onchocerca volvulus sowie deren verwendung
CY1119579T1 (el) Μεθοδος για τη θεραπεια διαταραχων αναπτυξης της τριχας, οπως η γυναικειου τυπου αλωπεκια και συνεπως χρησιμα σκευασματα
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
DE60324387D1 (de) Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
BRPI0409475A (pt) inibição de vav na rejeição de enxerto
NO20060420L (no) 2-aminobenzoylderivater
DE59510674D1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties